Indonesia Energy Corporation Limited vs Repligen Corporation Common Stock — how do they compare? Indonesia Energy Corporation Limited trades at $2.66 (market cap $41.08M), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 275.3× Indonesia Energy Corporation Limited's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indonesia Energy Corporation Limited for 24 Days and Repligen Corporation Common Stock for 0 Days on average.
| INDO | RGEN | |
|---|---|---|
Market Cap | $41.08M | $11.31B |
Volume | 144,476 | 1,216,919 |
Sector | Energy | Health |
52-Week High | $6.74 | $194.57 |
52-Week Low | $2.49 | $102.87 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $36.02M | $11.20B |
Signals from Pluang's Aura AI — not financial advice
INDO trades at $2.75 with minimal daily movement (+0.36%). The stock shows bearish technical signals despite unanimous analyst buy ratings. Fundamentally, the company faces significant challenges with negative profit margins (-152.72% net income margin) and consistent quarterly losses, though recent oil discoveries at the K-29 well provide operational optimism. Cash flow remains dependent on financing activities to offset negative operational cash flow.
While analyst consensus remains bullish with 100% buy ratings, the stock presents high-risk exposure due to persistent unprofitability and negative cash generation. The company's exploration success offers potential upside, but investors face substantial execution risk and financial instability in the near term.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →